Evolving content that comments on relevance and implications of NAD research
Aging results in a gradual loss of skeletal muscle function over time. Sarcopenia, the progressive loss of skeletal muscle mass, strength, and performance with age, is one of the critical causes of functional decline in aged adults. Essential for supporting breathing, as well as moving and maintaining posture and balance, skeletal muscle makes up nearly 40% of a young, healthy individual’s total body mass and decreases between 3 to 8% each decade after 30 years of age.
Read MoreAtaxia telangiectasia (AT) is a rare, inherited neurodegenerative disorder characterized by cerebellar degeneration, immunodeficiency, and cancer predisposition. Previous preclinical research has shown that increasing NAD+ through nicotinamide riboside (NR), a vitamin B3 form, improved neurodegeneration and neuromuscular function in mouse models of AT. These results indicate that NAD+ boosting may be a potential therapeutic strategy for AT. Researchers of this study set out to investigate the effects of boosting NAD with NR in AT patients.
Read MoreRaising NAD+ levels with nicotinamide riboside has been shown, in animal models, to reduce pain resulting from the cancer treating drug therapy paclitaxel. When administered to rodents in combination with paclitaxel, NR also helped to further decrease tumor growth, suggesting NR may enhance the drug’s tumor-suppressing effects.
Read MoreA new study assessing whether administration of a mixture of Combined Metabolic Activators (CMAs), including NAD+ precursor nicotinamide riboside (NR), could treat Parkinson’s disease patients, is now available on the open access preprint publication server medRxiv.org.
Parkinson’s Disease (PD) is a neurodegenerative disease largely characterized by impairments in motor functions, including tremors, stiffness, slow movement, or difficulty in maintaining balance, as well as in non-motor functions, such as cognitive impairment [1]. Those who suffer from PD may also experience mental and behavioral changes, memory difficulties, and depression.
Read MoreResults of a new phase 2 clinical study assessing whether administration of a mixture of Combined Metabolic Activators (CMAs) including NAD+ precursor nicotinamide riboside (NR) could treat Alzheimer’s Disease patients, are now available on the open access preprint publication server medRxiv.org.
Alzheimer’s Disease (AD), a neurodegenerative disease characterized by impaired memory and cognitive decline, affects more than 44 million people worldwide [1, 2]. The disease not only causes tremendous human suffering, but also puts an enormous strain on the healthcare system, families, and federal budget.
Read More
